Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors. The CNTX news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how its pipeline and corporate activities evolve over time.
According to recent announcements, Context is advancing three key programs: CTIM-76, a Claudin 6 x CD3 TCE in a Phase 1 dose-escalation trial for CLDN6-positive ovarian, endometrial, and testicular cancers; CT-95, a Mesothelin x CD3 TCE in a Phase 1 study for mesothelin-expressing solid tumors such as pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers; and CT-202, a Nectin-4 x CD3 TCE in preclinical development with pH-dependent activity designed for the tumor microenvironment. News items often highlight clinical enrollment updates, early safety and anti-tumor activity signals, and preclinical data presented at major oncology meetings.
Investors and followers of CNTX can also see updates on quarterly operating and financial results, at-the-market equity program changes, Nasdaq listing compliance notices and resolutions, and organizational developments such as inducement stock option grants and senior leadership appointments. The company regularly reports participation in scientific and investor conferences, including ASCO, AACR, SITC, and healthcare investment forums, which can signal upcoming data disclosures or corporate visibility efforts.
Use this page to review Context Therapeutics’ latest clinical, financial, and corporate news in one place. For those tracking immuno-oncology and T cell engager developments in solid tumors, the CNTX news stream provides a consolidated view of the company’s reported progress and key milestones.
Context Therapeutics (Nasdaq: CNTX) announced a collaboration with Menarini Group to support a Phase 1b/2 clinical trial of ONA-XR, an oral progesterone receptor antagonist, combined with elacestrant, a selective estrogen receptor degrader. Targeting ER+, PR+, HER2- metastatic breast cancer patients previously treated with a CDK4/6 inhibitor, this trial aims to explore enhanced tumor control through dual ER and PR blockade. Elacestrant showed a 30% reduction in progression risk compared to standard therapies. The trial is set to initiate in Q4 2022.
Context Therapeutics Inc. (Nasdaq: CNTX) reported its Q1 2022 financial results, revealing a net loss of $3.4 million compared to $0.9 million in Q1 2021. Cash and cash equivalents declined to $45.7 million from $49.7 million at year-end 2021. The company presented promising data from its ONA-XR clinical trial at the AACR Annual Meeting and has ongoing Phase 2 trials for breast, ovarian, and endometrial cancers. Preliminary data from these trials is expected later in 2022, alongside the selection of a candidate for the CLDN6xCD3 program.
Context Therapeutics Inc. (Nasdaq: CNTX) announced promising results from its Phase 2 trial of ONA-XR, a progesterone receptor antagonist, in treating advanced granulosa cell tumors. The results will be presented at the ASCO Annual Meeting scheduled for June 3-7, 2022. The study has progressed to evaluate ONA-XR in combination with the antiestrogen anastrozole. CEO Martin Lehr expressed optimism about ONA-XR's potential in targeting this rare ovarian cancer type. The abstract highlights significant activity of ONA-XR, marking a pivotal step in Context's clinical program for women's oncology therapies.
Context Therapeutics announced promising preclinical results for its lead candidate, ONA-XR, a progesterone receptor antagonist, at the AACR Annual Meeting 2022. The data showcases ONA-XR's potential in combination with standard therapies for hormone-positive tumors, demonstrating significant tumor regression in various preclinical models. Additionally, the company is progressing with its CLDN6xCD3 bispecific antibody program, aiming for candidate selection for IND-enabling studies by year-end. Preliminary data from ongoing Phase 2 trials is expected later this year.
Context Therapeutics announced that CEO Martin Lehr will participate in two virtual investor conferences in April 2022. The events include Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference on April 14 at 8:30 a.m. ET and the 21st Annual Needham Virtual Healthcare Conference on the same day at 2:15 p.m. ET. Context is focused on developing small molecule and immunotherapy treatments for breast and gynecological cancers, with its lead candidate ONA-XR undergoing multiple clinical trials.
Context Therapeutics (Nasdaq: CNTX) announced financial results for the year ending December 31, 2021, reporting a net loss of $10.5M compared to a net income of $6.6M in 2020. The company raised $28.75M from its IPO and $31.25M in a private placement, strengthening its cash position to $49.7M, sufficient to fund operations into 2024. Context highlighted positive preclinical data for its ONA-XR candidate and plans for upcoming Phase 2 clinical trial data. The company expects preliminary results from several trials in mid-2022 and aims to introduce a new bispecific antibody candidate for ovarian and endometrial cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) has announced that five abstracts will be presented at the AACR Annual Meeting 2022 from April 8-13 in New Orleans, LA. The company is focusing on its lead product candidate, onapristone extended release (ONA-XR), aimed at treating various hormone-driven female cancers. A webinar is scheduled for April 13, 2022, at 11 a.m. ET, where management will discuss these presentations and provide updates on ONA-XR's clinical program. Context has a robust clinical pipeline, including multiple ongoing trials for its promising therapies.
Context Therapeutics Inc. (Nasdaq: CNTX) announced that CEO Martin Lehr will present at the Sachs 15th Annual European Life Sciences CEO Forum on March 1-2, 2022, with on-demand viewing available. The company will also engage in one-on-one meetings from February 28 to March 4, 2022. Context focuses on developing small molecule and immunotherapy treatments for breast and gynecological cancers, particularly its lead candidate, ONA-XR, which is undergoing several clinical trials. For more details, visit their website.
Context Therapeutics announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D. as VP of R&D, effective January 5, 2022. These appointments come as the company approaches pivotal phases in its pipeline, particularly with its lead product candidate ONA-XR for treating women's cancers. The current Head of CMC, Bill Rencher, Ph.D., will transition to an advisory role. The new leadership team aims to advance research and development initiatives within the company, focusing on effective treatments for hormone-driven cancers.
Context Therapeutics (Nasdaq: CNTX), a women's oncology company, announced that CEO Martin Lehr will participate in two upcoming investor conferences in January 2022. The Biotech Showcase™ 2022 conference is set for January 10-12, with Lehr's panel on women's health scheduled for January 12 at 8 a.m. PST. Additionally, Context will present at the Edison Group Open House: Global Healthcare 2022 from January 25-27 and will hold one-on-one meetings. Context is focused on developing treatments for breast and gynecological cancers, with ongoing clinical trials for its lead candidate, ONA-XR.